Deferred modification of antiretroviral regimen following documented treatment failure in Asia

Results from the TREAT Asia HIV Observational Database (TAHOD)

J. Zhou, P. C.K. Li, N. Kumarasamy, M. Boyd, Y. M.A. Chen, T. Sirisanthana, S. Sungkanuparph, S. Oka, G. Tau, P. Phanuphak, V. Saphonn, F. J. Zhang, S. F.S. Omar, C. K.C. Lee, R. Ditangco, T. P. Merati, P. L. Lim, JunYong Choi, M. G. Law, S. Pujari

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: The aim of the study was to examine the rates and predictors of treatment modification following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in the TREAT Asia HIV Observational Database (TAHOD). Methods: Treatment failure (immunological, virological and clinical) was defined by World Health Organization criteria. Countries were categorized as high or low income by World Bank criteria. Results: Among 2446 patients who initiated cART, 447 were documented to have developed treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed at least one drug after failure (51.6 per 100 person-years). There was no difference between patients from high- and low-income countries [adjusted hazard ratio (HR) 1.02; . P=0.891]. Advanced disease stage [Centers for Disease Control and Prevention (CDC) category C . vs. A; adjusted HR 1.38, . P=0.040], a lower CD4 count (≥51 cells/μL . vs. ≤50 cells/μL; adjusted HR 0.61, . P=0.022) and a higher HIV viral load (≥400 HIV-1 RNA copies/mL . vs. <400 copies/mL; adjusted HR 2.69, . P<0.001) were associated with a higher rate of treatment modification after failure. Compared with patients from low-income countries, patients from high-income countries were more likely to change two or more drugs (67% . vs. 49%; . P=0.009) and to change to a protease-inhibitor-containing regimen (48% . vs. 16%; . P<0.001). Conclusions: In a cohort of Asian patients with HIV infection, nearly half remained on the failing regimen in the first year following documented treatment failure. This deferred modification is likely to have negative implications for accumulation of drug resistance and response to second-line treatment. There is a need to scale up the availability of second-line regimens and virological monitoring in this region.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalHIV Medicine
Volume11
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Treatment Failure
HIV
Databases
Therapeutics
United Nations
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Protease Inhibitors
Viral Load
Drug Resistance
Pharmaceutical Preparations
HIV Infections
HIV-1
RNA

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Zhou, J. ; Li, P. C.K. ; Kumarasamy, N. ; Boyd, M. ; Chen, Y. M.A. ; Sirisanthana, T. ; Sungkanuparph, S. ; Oka, S. ; Tau, G. ; Phanuphak, P. ; Saphonn, V. ; Zhang, F. J. ; Omar, S. F.S. ; Lee, C. K.C. ; Ditangco, R. ; Merati, T. P. ; Lim, P. L. ; Choi, JunYong ; Law, M. G. ; Pujari, S. / Deferred modification of antiretroviral regimen following documented treatment failure in Asia : Results from the TREAT Asia HIV Observational Database (TAHOD). In: HIV Medicine. 2010 ; Vol. 11, No. 1. pp. 31-39.
@article{698669214f424124b0854b1fff3928dc,
title = "Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)",
abstract = "Objective: The aim of the study was to examine the rates and predictors of treatment modification following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in the TREAT Asia HIV Observational Database (TAHOD). Methods: Treatment failure (immunological, virological and clinical) was defined by World Health Organization criteria. Countries were categorized as high or low income by World Bank criteria. Results: Among 2446 patients who initiated cART, 447 were documented to have developed treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed at least one drug after failure (51.6 per 100 person-years). There was no difference between patients from high- and low-income countries [adjusted hazard ratio (HR) 1.02; . P=0.891]. Advanced disease stage [Centers for Disease Control and Prevention (CDC) category C . vs. A; adjusted HR 1.38, . P=0.040], a lower CD4 count (≥51 cells/μL . vs. ≤50 cells/μL; adjusted HR 0.61, . P=0.022) and a higher HIV viral load (≥400 HIV-1 RNA copies/mL . vs. <400 copies/mL; adjusted HR 2.69, . P<0.001) were associated with a higher rate of treatment modification after failure. Compared with patients from low-income countries, patients from high-income countries were more likely to change two or more drugs (67{\%} . vs. 49{\%}; . P=0.009) and to change to a protease-inhibitor-containing regimen (48{\%} . vs. 16{\%}; . P<0.001). Conclusions: In a cohort of Asian patients with HIV infection, nearly half remained on the failing regimen in the first year following documented treatment failure. This deferred modification is likely to have negative implications for accumulation of drug resistance and response to second-line treatment. There is a need to scale up the availability of second-line regimens and virological monitoring in this region.",
author = "J. Zhou and Li, {P. C.K.} and N. Kumarasamy and M. Boyd and Chen, {Y. M.A.} and T. Sirisanthana and S. Sungkanuparph and S. Oka and G. Tau and P. Phanuphak and V. Saphonn and Zhang, {F. J.} and Omar, {S. F.S.} and Lee, {C. K.C.} and R. Ditangco and Merati, {T. P.} and Lim, {P. L.} and JunYong Choi and Law, {M. G.} and S. Pujari",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1468-1293.2009.00738.x",
language = "English",
volume = "11",
pages = "31--39",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "1",

}

Zhou, J, Li, PCK, Kumarasamy, N, Boyd, M, Chen, YMA, Sirisanthana, T, Sungkanuparph, S, Oka, S, Tau, G, Phanuphak, P, Saphonn, V, Zhang, FJ, Omar, SFS, Lee, CKC, Ditangco, R, Merati, TP, Lim, PL, Choi, J, Law, MG & Pujari, S 2010, 'Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD)', HIV Medicine, vol. 11, no. 1, pp. 31-39. https://doi.org/10.1111/j.1468-1293.2009.00738.x

Deferred modification of antiretroviral regimen following documented treatment failure in Asia : Results from the TREAT Asia HIV Observational Database (TAHOD). / Zhou, J.; Li, P. C.K.; Kumarasamy, N.; Boyd, M.; Chen, Y. M.A.; Sirisanthana, T.; Sungkanuparph, S.; Oka, S.; Tau, G.; Phanuphak, P.; Saphonn, V.; Zhang, F. J.; Omar, S. F.S.; Lee, C. K.C.; Ditangco, R.; Merati, T. P.; Lim, P. L.; Choi, JunYong; Law, M. G.; Pujari, S.

In: HIV Medicine, Vol. 11, No. 1, 01.01.2010, p. 31-39.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Deferred modification of antiretroviral regimen following documented treatment failure in Asia

T2 - Results from the TREAT Asia HIV Observational Database (TAHOD)

AU - Zhou, J.

AU - Li, P. C.K.

AU - Kumarasamy, N.

AU - Boyd, M.

AU - Chen, Y. M.A.

AU - Sirisanthana, T.

AU - Sungkanuparph, S.

AU - Oka, S.

AU - Tau, G.

AU - Phanuphak, P.

AU - Saphonn, V.

AU - Zhang, F. J.

AU - Omar, S. F.S.

AU - Lee, C. K.C.

AU - Ditangco, R.

AU - Merati, T. P.

AU - Lim, P. L.

AU - Choi, JunYong

AU - Law, M. G.

AU - Pujari, S.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Objective: The aim of the study was to examine the rates and predictors of treatment modification following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in the TREAT Asia HIV Observational Database (TAHOD). Methods: Treatment failure (immunological, virological and clinical) was defined by World Health Organization criteria. Countries were categorized as high or low income by World Bank criteria. Results: Among 2446 patients who initiated cART, 447 were documented to have developed treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed at least one drug after failure (51.6 per 100 person-years). There was no difference between patients from high- and low-income countries [adjusted hazard ratio (HR) 1.02; . P=0.891]. Advanced disease stage [Centers for Disease Control and Prevention (CDC) category C . vs. A; adjusted HR 1.38, . P=0.040], a lower CD4 count (≥51 cells/μL . vs. ≤50 cells/μL; adjusted HR 0.61, . P=0.022) and a higher HIV viral load (≥400 HIV-1 RNA copies/mL . vs. <400 copies/mL; adjusted HR 2.69, . P<0.001) were associated with a higher rate of treatment modification after failure. Compared with patients from low-income countries, patients from high-income countries were more likely to change two or more drugs (67% . vs. 49%; . P=0.009) and to change to a protease-inhibitor-containing regimen (48% . vs. 16%; . P<0.001). Conclusions: In a cohort of Asian patients with HIV infection, nearly half remained on the failing regimen in the first year following documented treatment failure. This deferred modification is likely to have negative implications for accumulation of drug resistance and response to second-line treatment. There is a need to scale up the availability of second-line regimens and virological monitoring in this region.

AB - Objective: The aim of the study was to examine the rates and predictors of treatment modification following combination antiretroviral therapy (cART) failure in Asian patients with HIV enrolled in the TREAT Asia HIV Observational Database (TAHOD). Methods: Treatment failure (immunological, virological and clinical) was defined by World Health Organization criteria. Countries were categorized as high or low income by World Bank criteria. Results: Among 2446 patients who initiated cART, 447 were documented to have developed treatment failure over 5697 person-years (7.8 per 100 person-years). A total of 253 patients changed at least one drug after failure (51.6 per 100 person-years). There was no difference between patients from high- and low-income countries [adjusted hazard ratio (HR) 1.02; . P=0.891]. Advanced disease stage [Centers for Disease Control and Prevention (CDC) category C . vs. A; adjusted HR 1.38, . P=0.040], a lower CD4 count (≥51 cells/μL . vs. ≤50 cells/μL; adjusted HR 0.61, . P=0.022) and a higher HIV viral load (≥400 HIV-1 RNA copies/mL . vs. <400 copies/mL; adjusted HR 2.69, . P<0.001) were associated with a higher rate of treatment modification after failure. Compared with patients from low-income countries, patients from high-income countries were more likely to change two or more drugs (67% . vs. 49%; . P=0.009) and to change to a protease-inhibitor-containing regimen (48% . vs. 16%; . P<0.001). Conclusions: In a cohort of Asian patients with HIV infection, nearly half remained on the failing regimen in the first year following documented treatment failure. This deferred modification is likely to have negative implications for accumulation of drug resistance and response to second-line treatment. There is a need to scale up the availability of second-line regimens and virological monitoring in this region.

UR - http://www.scopus.com/inward/record.url?scp=72449184068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449184068&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2009.00738.x

DO - 10.1111/j.1468-1293.2009.00738.x

M3 - Article

VL - 11

SP - 31

EP - 39

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 1

ER -